Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy

Cancer Journal from Scientific American

Volumn 4, Issue 1, 1998, Pages 52-58

  Perez, Edith A ^a   Lembersky, Barry ^b   Kaywin, Paul ^c   Kalman, Leonard ^c   Yocom, Karen ^d   Friedman, Carl ^d  

^a MAYO CLINIC   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c Oncol Hematol Grp of S Florida   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CANNABINOID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; VOMITING;

EID: 0031934550     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chevallier B on behalf of the Granisetron Study Group. The control of acute cisplatin-induced emesis - a comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993;68:176-180.
2. De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834-840.
3. Hainsworth JD, Hesketh PJ. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol 1992;19[suppl 15]:14-16.
4. Depierre A, Lebeau B, d' Allens H. A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. Oncology 1992;49:305-311.
5. Soukop M on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Supportive Care Cancer 1994;3:177-181.
6. Hainsworth J, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-728.
7. Mughal TI, Dowse L, Neill KO et al. Role of ondansetron in controlling cytotoxic chemotherapy-induced emesis. Cancer Research Therapy Control 1994;4:39-42.
8. Marty M on behalf of the Granisetron Study Group. A comparative study on the use of granisetron, a selective 5-HT3 antagonist, versus a standard antiemetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26[suppl 1]:S28-S32.
9. Bonneterre J, Hecquet B on behalf of the French Northern Oncology Group. Granisetron IV compared with ondansetron IV plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized crossover study. Bull Cancer (Paris) 1995;82:1038-1043.
10. Jantunen IT, Muhonen TT, Kataja VV et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer 1993;29A:1669-1672.
11. Noble A, Bremer K, Goedhals L et al. A double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30A:1083-1088.
12. Perez EA. Comparative clinical efficacy and safety of 5-HT3 receptor antagonists for chemotherapy-induced emesis. Hospital Formulary 1994;29[suppl 5]:S18-S23.
13. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter, double-blind, randomized, parallel group study. Oncology 1994;51:113-118.
14. Navari R, Gandara D, Hesketh P et al. A comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248.
15. Mainland D: Elementary Medical Statistics (2nd ed). Philadelphia: Saunders, 1963.
16. France LA, Lewis JA, Kay R. Analysis of failure time data in crossover studies. Stat Med 1991;10:1099-1113.
17. Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995;13:2417-2426.
18. Gebbia V, Cannata G, Testa A et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trial. Cancer 1994;74: 1945-1952.
19. Fraschini G. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol 1992;19:41-47.
20. Riviere A on behalf of the Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967-971.
21. Grunberg SM, Stevenson LL, Russell CA et al. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7:1137-1141.